Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Dyne Therapeutics (Nasdaq: DYN) announced that John Cox, president and chief executive officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET).
A live webcast will be available in the Investors & Media section of Dyne’s website and a replay will be accessible for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – DYN
On the day this news was published, DYN gained 7.01%, reflecting a notable positive market reaction. Argus tracked a trough of -7.7% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $210M to the company's valuation, bringing the market cap to $3.21B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Key biotech peers in Pharmaceutical Preparations showed positive moves (e.g., SRPT +5.6%, MESO +1.42%, PROK +2.97%), while DYN was down 0.6%, indicating stock-specific dynamics rather than a uniform sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Board appointment | Positive | -1.8% | New director with commercialization and large acquisition integration experience. |
| Dec 11 | Equity offering close | Negative | -0.8% | Closing of upsized common stock offering with full underwriter option exercise. |
| Dec 09 | Equity offering pricing | Negative | -16.9% | Pricing of upsized $350M underwritten common stock offering at set share price. |
| Dec 08 | Equity offering launch | Negative | +9.5% | Announcement of proposed $300M common stock offering with underwriter option. |
| Dec 08 | Clinical trial results | Positive | +9.5% | Positive topline Phase 1/2 DELIVER trial results for z-rostudirsen in DMD. |
Recent history shows negative reactions to equity offerings, but positive alignment with favorable clinical data and mixed response to corporate/financing announcements.
Over the last months, Dyne reported several financings and key clinical progress. A positive Phase 1/2 DELIVER trial update on Dec 8, 2025 saw a +9.47% move, aligning with the good data. Multiple December 2025 equity offerings raised capital but coincided with share pressure, notably a -16.94% reaction to an upsized offering pricing. A board appointment linked to future commercialization on Dec 23, 2025 saw a modest decline. Today’s conference presentation fits into ongoing investor outreach rather than a new clinical or financing catalyst.
Market Pulse Summary
The stock moved +7.0% in the session following this news. A strong positive reaction aligns with prior enthusiasm for Dyne’s clinical and strategic milestones, such as the +9.47% move on positive DELIVER data. However, recent sizeable equity raises totaling over $402.5M have added supply to the float, which historically weighed on the stock. If gains followed a conference appearance, investors would need to consider whether buying enthusiasm could fade as financing overhang and insider net selling in the last 90 days reassert themselves.
AI-generated analysis. Not financial advice.
WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET).
A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 30 days.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
FAQ
When will Dyne Therapeutics (DYN) present at the J.P. Morgan Healthcare Conference?
Who will represent Dyne Therapeutics (DYN) at the January 14, 2026 presentation?
Where can investors watch Dyne Therapeutics (DYN) live from J.P. Morgan on January 14, 2026?
How long will the replay of Dyne Therapeutics (DYN) presentation be available after January 14, 2026?
What topics will Dyne Therapeutics (DYN) cover at the 44th Annual J.P. Morgan Healthcare Conference?
How can I find the Dyne Therapeutics (DYN) webcast link for the January 14, 2026 presentation?
